Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NC 4.0The Oncologist

Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer

Related

  1. Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
    Jane McKenzie, Lauren Howard, Joseph J. Park +13
    Prostate Cancer and Prostatic DiseasesPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
    Georges Gebrael, Yeonjung Jo, Varun Nandakumar +14
    JAMA network openPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCCrossref
  3. Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence
    G. Huang, M. A. Lorenzana Carrillo, H. Chen +14
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling.
    Seunggyun Ha, Joo Hyun O, Chansoo Park +6
    PharmaceuticsPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  5. The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{nandakumar2026exceptional,
  title = {{Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer}},
  author = {Varun Nandakumar and Georges Gebrael and Neeraj Agarwal},
  journal = {The Oncologist},
  year = {2026},
  month = oct,
  doi = {10.1093/oncolo/oyag412},
  url = {https://doi.org/10.1093/oncolo/oyag412},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
AU  - Varun Nandakumar
AU  - Georges Gebrael
AU  - Neeraj Agarwal
PY  - 2026
DA  - 2026/10/26
JO  - The Oncologist
DO  - 10.1093/oncolo/oyag412
UR  - https://doi.org/10.1093/oncolo/oyag412
SN  - 1083-7159
SN  - 1549-490X
ER  -